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Summary
Glioblastoma (GBM) is an aggressive cancer with a very poor prognosis. 
Generally viewed as weakly immunogenic, GBM responds poorly to cur-
rent immunotherapies. To understand this problem more clearly we used 
a combination of natural killer (NK) cell functional assays together with 
gene and protein expression profiling to define the NK cell response to 
GBM and explore immunosuppression in the GBM microenvironment. In 
addition, we used transcriptome data from patient cohorts to classify GBM 
according to immunological profiles. We show that glioma stem-like cells, a 
source of post-treatment tumour recurrence, express multiple immunomod-
ulatory cell surface molecules and are targeted in preference to normal 
neural progenitor cells by natural killer (NK) cells  ex vivo. In contrast, 
GBM-infiltrating NK cells express reduced levels of activation receptors 
within the tumour microenvironment, with hallmarks of transforming 
growth factor (TGF)-β-mediated inhibition. This NK cell inhibition is ac-
companied by expression of multiple immune checkpoint molecules on T 
cells. Single-cell transcriptomics demonstrated that both tumour and 
haematopoietic-derived cells in GBM express multiple, diverse mediators 
of immune evasion. Despite this, immunome analysis across a patient 
cohort identifies a spectrum of immunological activity in GBM, with ac-
tive immunity marked by co-expression of immune effector molecules and 
feedback inhibitory mechanisms. Our data show that GBM is recognized 
by the immune system but that anti-tumour immunity is restrained by 
multiple immunosuppressive pathways, some of which operate in the healthy 
brain. The presence of immune activity in a subset of patients suggests 
that these patients will more probably benefit from combination immu-
notherapies directed against multiple immunosuppressive pathways.
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Introduction
Glioblastoma (GBM) is the most common and aggressive 
type of primary adult brain cancer. Current treatments 
include debulking neurosurgery and adjuvant chemo/
radiotherapy. Despite these therapies, median overall sur-
vival is just 12–24 months [1]. Recent developments in 
cancer immunotherapy provide one potential approach to 
improve patient outcomes [2]. However, despite significant 
therapeutic impact on several solid tumour types, immune 
checkpoint blockade (ICB) is yet to demonstrate benefit 
in GBM treatment [3].
Evasion of host immunity is a hallmark of cancer [4]. 
Tumours exploit the negative feedback mechanisms that 
the healthy immune system uses to dampen immune 
responses. These mechanisms include the recruitment of 
immune cells with suppressive activity, the expression of 
immunosuppressive cytokines, such as transforming growth 
factor (TGF)-β and immune checkpoints, including pro-
grammed cell death (PD)-1 and cytotoxic T lymphocyte 
antigen (CTLA)-4 [5]. Chronic interactions between tumour 
cells and infiltrating T cells leads to an exhausted phe-
notype, an unresponsive but reversible state with an altered 
transcriptional profile [6]. Exhausted tumour-infiltrating 
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lymphocytes express immune checkpoints, and antibodies 
that target these molecules can reinvigorate anti-tumour 
immunity [7].
Mutations in the tumour genome are a source of neo-
antigens and mutation frequency is a surrogate marker for 
immunogenicity [8]. For several tumours, neoantigen load 
is correlated with survival and with response to immune 
checkpoint blockade; melanoma and lung adenocarcinoma 
have higher mutational load, greater T cell infiltration, greater 
PD-1 expression and consequently show better responses 
to anti-PD-1 therapy [9]. Compared to other solid tumours, 
mutation frequency and T cell infiltration levels in GBM 
are low. However, GBM-infiltrating T cells have been isolated 
against a number of germline-encoded antigens over-
expressed in the tumour, indicating that T cell responses 
are at least possible [10]. Glioblastoma cells are a target 
for natural killer (NK) cells; however, the number of GBM-
infiltrating natural killer (NK) cells is also low [11]. The 
paucity of NK cells and T cells in GBM is compounded 
by the high proportion of suppressive myeloid-lineage cells 
[12] able to suppress lymphocyte function [5].
Importantly, GBM-infiltrating T cells express PD-1 [13], 
yet reports of initial anti-PD-1 (nivolumab) clinical trials 
are not encouraging [2]. This indicates that PD-1 expres-
sion per se is not sufficient to allow responsiveness to 
therapy, and that additional suppressive components of 
the GBM immune landscape regulate many effectors of 
anti-tumour immunity.
Here we show that, in vitro, GBM cells are recognized 
and killed by NK cells; however, NK cells derived from 
GBM tumours have an altered cell surface phenotype 
consistent with their inhibition in the tumour microen-
vironment. We have explored the basis of this inhibition 
and identify numerous immunosuppressive mechanisms 
operating in GBM contributed by both tumour and immune 
cell compartments. These immunosuppressive pathways, 
some of which appear to operate in the normal brain, 
are a barrier to effective immunotherapy, but also represent 
candidate therapeutic targets to reinvigorate tumour NK 
cell interactions.
Materials and methods
Ethics statement
Ethical approval for this study was granted by the ethics 
committee at the Leeds Teaching Hospitals NHS Trust, 
Leeds UK (REC number 10-H1306-7).
Classification of GBM patients consensus immune 
cluster (CIC)
CIC classification [14] was applied to GBM tumour tran-
scriptome data from The Cancer Genome Atlas (TCGA). 
Briefly, consensus cluster analysis of melanomas used the 
expression of 380 genes specific to 24 immune cell types 
([15]; this produced six subtypes which we termed CICs. 
The average expression of each gene within each CIC is 
the cluster centroid. Using TCGA data, we used the near-
est centroid method [16] to classify each GBM tumour 
into one of the CICs according to the highest Spearman’s 
correlation coefficient with the centroids. For each of the 
24 immune cell types of the immunome compendium 
[15], we calculated a score per GBM tumour, graphically 
represented using a heatmap.
Differential expression of genes in GBM CIC2 and 
CIC4 and in REMBRANDT data
To compare the expression of selected genes in different 
patient groups we used RNAseq data from TCGA [obtained 
via The Cancer Imaging Archive (TCIA) [7]], assigning 
patients to either CIC2 or CIC4 (as above). In addition, 
we used microarray data from the REMBRANDT study 
[17] downloaded from Betastasis.com. For REMBRANDT, 
patient samples were classified as granzyme A (GZMA)high 
expressors or GZMAlow expressors based on the median 
expression value (n  =  214). Expression of selected genes 
was compared between CIC2 and CIC4 (for TCGA data) 
or the GZMAhigh and GZMAlow patients (for 
REMBRANDT) and analysed using non-parametric, 
unpaired statistical testing (using GraphPad Prism).
Single-cell data and normal brain analysis
Single-cell (sc)RNAseq data were downloaded from [18] 
and expression of candidate genes analysed. Data were 
visualized using rStudio version 1.0.143 (package: gplots 
3.0.1) using heatmap.2. Untransformed data clustering 
(unsupervised) was performed (Euclidean distance). 
Individual cells were classified as ‘tumour’ or ‘immune’ 
according to co-expression of SRY-box transcription factor 
9 (SOX9) and epidermal growth factor receptor (EGFR) 
[18] and protein tyrosine phosphatase receptor type C 
(PTPRC), respectively. For all genes, expression of >  0 
was scored positive. For immune (PTPRC+) and tumour 
(SOX9+EGFR+) cells, the number of different immunomod-
ulatory molecules expressed was counted for each cell 
and the percentage of immune and non-immune cells 
expressing immunomodulatory genes plotted. Expression 
of individual genes in non-tumour-bearing brain tissue 
was downloaded from [19]. These data are also available 
(with graphical output) at BrainRNAseq.org.
Tumour tissue and blood, collection and processing
After ethical approval and informed consent, tumours were 
resected and stored in phosphate-buffered saline (PBS) or 
within the cavitron ultrasonic surgical aspirator (CUSA) 
[20]. Samples were washed in PBS, CUSA samples were 
prepared as shown by Schroeteler et al. [20] and all 
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samples were filtered through a 40-µm cell strainer, washed 
twice in PBS, centrifuged at 400  g for 5  min and resus-
pended in PBS, 0·5% bovine serum albumin (BSA) and 
0·05% sodium azide. Matched patient blood was diluted 
with PBS, layered over Ficoll (Axis-Shield PoC, Oslo, 
Norway) and centrifuged at 800  g for 20  min. Tumour 
and blood-derived cells were stained with appropriate 
antibodies and isotype controls (see Supporting informa-
tion, Table S1), with single stain controls on tumour samples 
used for compensation during analysis using the cytexpert 
compensation matrix. All samples were run on a CytoFlex 
S (Beckman Coulter Life Sciences, Indianapolis, IN, USA) 
(see Supporting information, Table S1). Gated, isotype 
control stained, intratumoral or peripheral blood NK cells 
from each patient (Supporting information, Fig. S1) were 
assigned a gate of 2% positive, and specific antibody stain-
ing is reported within this gate.
Primary cells and cell lines
Neural progenitor cells (NP1) were isolated from a patient 
undergoing surgery to treat epilepsy [21]. The primary lines, 
GBM1 and NP1, were generated at the Scripps Institute. 
GBM11, GBM13 and GBM20 were derived at the University 
of Leeds using the same method and culture conditions 
[22]. Peripheral blood mononuclear cells (PBMC) were 
isolated from whole blood of healthy donors as above. NK 
cells were further separated using an NK cell isolation kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany), and cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and 10% human 
AB serum (Sigma-Aldrich, Gillingham, UK).
Surface antigen screening
GBM stem-like cell (GSC) lines were harvested using 
0·25% trypsin/ethylenediamine tetraacetic acid (EDTA) and 
fluorescently labelled for 60  min at 37°C and 5% CO2 in 
serum-free media with one of the the following cell dyes: 
0·4 μM cell trackerTM (CT)-green CMFDA (488  nm exci-
tation), 2 μM CTorange-CMRA (488 nm excitation), 2 μM 
CTviolet-BMQC (407  nm excitation) or 5  μM calcein 
blue-AM (407 nm excitation) (all from Invitrogen, Carlsbad, 
CA, USA) All populations were washed three times, mixed 
together and plated at a density of 1  ×  106 total cells/
well in 96-well round-bottomed plates (Nunc, Roskilde, 
Denmark). Cells were stained as per the manufacturer’s 
instructions with 242 antibodies from the BD Bioscience 
Lyoplate screening panel, followed by Zombie NIR 
(Biolegend, San Diego, CA, USA) for 30 min before resus-
pension and analysis by flow cytometry. Cells were gated 
based on their emitting fluorescence at 520  nm (CTgreen 
loaded), 580  nm (CTorange loaded), 540  nm (CTviolet 
loaded) or 449  nm (calcien blue loaded). The median 
fluorescence intensity (MFI) for each gated population, 
for each antigen and isotype control emission at 668  nm 
(Alexa647 emission) was generated and GSC lines scored 
as positive if more than 20% of the population expressed 
the antigen. Flow cytometer and settings are as described 
earlier; analysis was performed using FacsDiva (BD 
Biosciences, San Jose, CA, USA), FlowJo (Treestar, Inc., 
Ashland, OR, USA) and Kaluza (Beckman Coulter) 
software.
Natural killer cytotoxicity assays
Target tumour cell lines were labelled with the relevant cell 
dye (see surface screen) for 1  h at 37°C, washed twice and 
plated at 2  ×  105/well. NK cells were pre-activated with 
20 ng/ml interleukin (IL)-15 for 48 h and mixed with targets 
at the E  :  T ratios indicated. After 5  h, cells were pelleted 
(300 g for 5 min), washed with PBS and stained with Zombie 
NIR (Biolegend) for 15 min at room temperature. Competitive 
cytotoxicity assays were set up as above; the two target cell 
types under test (GBM and neural progenitors) were labelled 
with either CTgreen or CTviolet, mixed 1  :  1 and used as 
a target population at an E  :  T of 5  :  1.
Results
Glioma stem-like cells are effective targets of NK cells
Effective therapy for GBM will require the elimination of 
the radioresistant GSCs that are largely responsible for 
recurrence [23]. While tumour-associated antigen-specific 
T cells offer a highly selective therapeutic approach, antigen-
independent effector cells, such as NK cells, have the 
potential to target and destroy GBM tumour cells that 
have a low neoantigen load.
We used three patient-derived GSC lines [24] shown 
to exhibit a stem cell-like expression profile and recapitulate 
high-grade gliomas in orthotopic xenograft mouse models 
[22,24] and performed cytotoxicity assays using peripheral 
blood-derived, IL-15-activated NK cells to confirm NK 
cell-mediated killing. Tumour cells differentiated from GSCs 
are more sensitive to NK cell killing than the GSC them-
selves [26], but GSCs are killed by NK cells in the pres-
ence of activating cytokines (Fig. 1a) [25]. We further 
tested whether NK cells activated with IL-15 would be 
efficient killers of GSCs, but retain specificity for GSCs 
over normal neural progenitor cells. We performed an 
NK cytotoxicity assay using a mixed target cell population 
comprised of tumour GSC cells and normal neural pro-
genitor (NP) cells [22] at a ratio of 1  :  1. For all donors, 
IL-15-activated NK cells killed tumour cells in preference 
to the NP cells (Fig. 1b). These results suggest that, in 
short-term in-vitro cultures when sufficient immune cells 
are present and activated, GSCs are an effective and pref-
erential target for NK cells.
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Patient-derived NK cells exhibit an altered cell surface 
phenotype in GBM
The presence of infiltrating NK cells in GBM [11], coupled 
with their ability to recognize and kill GSCs (Fig. 1), sug-
gests that they are rendered non-functional in the GBM 
tumour microenvironment. We performed flow cytometry-
based analysis of intratumoural NK from GBM tissue and 
compared their surface phenotype to NK cells derived from 
autologous peripheral blood as well as blood from healthy 
donors. NK cell populations were defined as NKp46+ and 
CD3– due to high expression of CD56 (NCAM-1) on GBM 
tumour cells within the sample (Supporting information, 
Fig. S1). To confirm sampling of immune cells from within 
the GBM tumour tissue (and not from blood contamina-
tion of the tumour sample) we assayed the expression of 
PD-1 on T cells, and showed significantly enhanced expres-
sion of PD1 on tumour-derived T cells compared to their 
blood counterparts (Fig. 2a). Expression levels of NK cell 
surface molecules were similar on the blood-derived NK 
cells from both healthy donors and GBM patients. However, 
the expression of the tumour-sensing NK cell-activating 
receptors NKp30, NKG2D and DNAX accessory molecule-1 
(DNAM-1) and the surface molecules tetherin/CD317 and 
CD2 were all significantly reduced on the GBM 
Fig. 1. Natural killer (NK) cell-mediated killing of glioma stem-like cells. (a) NK cell cytotoxicity: cell tracker violet-labelled glioblastoma (GB) 
stem-like cell (GSC) lines (targets) were co-cultured with unlabelled, interleukin (IL)-15 activated NK cells (effectors) for 5 h at effector : target (E : T) 
ratios as shown. Co-cultures were then stained with a live/dead discriminator. The panel on the left shows identification of effector and target cells in 
the co-culture (for gating purposes) and the panels to the right show death of the labelled target cells at the different E : T ratios. The zero hour control 
is included as background cell death of the GSC cells. The three graphs summarize data obtained using three GSC lines (GBM1, GBM4 and GBM20) 
and three different NK cell donors (coloured dots), with standard deviation from the mean. (b) NK cell specificity: cytotoxicity assays of IL-15-
activated NK cells co-cultured with a 1 : 1 mix of the GSC line (indicated) and neural progenitor cells (NP). The GSC and NP lines were labelled with 
different cell tracker dyes, allowing their fate in the assay to be determined separately. The flow cytometry plots show the percentage of dead GSC (here 
GBM4) and NP cells after zero and 5 h co-culture with NK cells. The graphs summarize these data for assays containing the three GSC lines using NK 
cells from four separate donors (coloured dots), with standard deviation from the mean.
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tumour-derived NK cells compared to those from matched 
peripheral blood (Fig. 2b). Together with higher expression 
of PD-1 on GBM-derived T cells compared to matched 
peripheral blood (Fig. 2a), we also found higher expression 
of lymphocyte-activation gene (LAG-3) and CTLA-4 
(although differences in CTLA-4 expression did not reach 
statistical significance) (Supporting information, Fig. S2).
Members of the TGF-β family are highly expressed in 
GBM, and are important in maintaining the GSC pool 
[25]. Furthermore, we and others have previously shown 
that TGF-β reduces the expression of NKp30, NKG2D 
and DNAM-1 on NK cells and is associated with their 
functional inactivation [26,27]. Importantly, TGF-β induces 
the expression of the tetraspanin CD9 on NK cells [28], 
and we detected significantly increased expression of CD9 
on the surface of the GBM-resident NK cells compared 
to NK cells from matched peripheral blood (Fig. 2c). The 
reduced expression of NK cell activating receptors coupled 
with the increased expression of CD9 is suggestive of 
TGF-β-mediated evasion of NK cell cytotoxicity in the 
GBM microenvironment.
Collectively, GBM resident immune effector cells clearly 
demonstrate two separate phenotypes: the reduced expres-
sion of NK cell activation receptors and the increased 
expression of immune checkpoint molecules on T cells.
Surface antigen screening of GSCs identifies candidate 
immunomodulatory molecules
The GSC lines are selectively targeted by NK cells in 
vitro, but evade NK cells and other immune effector cells 
in vivo. To understand which immunomodulatory mol-
ecules expressed by GSC might be responsible for immune 
activation and inhibition, we analysed GSCs for the expres-
sion of cell surface immunomodulatory molecules. Using 
a flow cytometry-based screen, we identified 116 cell surface 
antigens expressed on four GSC lines lines (Supporting 
information, Table S1). Molecules detected on the GSCs 
included those associated with the cancer stem cell phe-
notype (CD24, CD44 and CD90) (Fig. 3a), as well as 
widely expressed cell surface molecules, such as major 
histocompatibility complex (MHC) class I (and 
β2-microglobulin), CD71 and CD98, as expected. Several 
immune inhibitory molecules were highly expressed, such 
as the immune checkpoint ligands programmed cell death 
ligand 1 (PD-L1) (CD274) and PD-L2 (CD273), providing 
a source for inhibition of PD-1 expressing T cells (Fig. 
3a). In addition, we found expression of the ectonucle-
otidase CD73 that, together with CD39, generates extracel-
lular adenosine to inhibit both NK cells and T cells via 
purinergic receptors [29], as well as expression of CD200 
and CD47, modulators of myeloid cell activity (Fig. 3a). 
Fig. 2. The cell surface phenotype of glioblastoma (GBM)-infiltrating lymphocytes. (a) Expression of programmed cell death 1 (PD-1) on CD3+ T cells 
in GBM patient tumour (GBM), patient blood (PB) and control blood from healthy donors (CB). Each dot represents a single patient sample (n is the 
number of GBM patient samples analysed); the bar indicates the mean ± standard deviation. The patient-derived tumour (GBM) and blood (PB) 
samples were analysed using a paired t-test; *P < 0·05, **P < 0·01; ***P < 0·001; n.s. = not significant. (b) Expression of NK cell surface molecules 
(gating on CD45+, NKp46+, CD3neg cells) in GBM patient tumour, patient blood and control blood from healthy donors as in (a). (c) Representative 
histograms of CD9 expression on PB and GBM-derived natural killer (NK) cells, grouped data as in (a). Statisical analysis was performed using a 
paired t-test. *P < 0·05, **P < 0·01.
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Ligands of NK cell activation receptors, such as MICA/B 
(NKG2D ligand) and CD112 (a DNAM-1 ligand), as well 
as CD80 (a T cell co-stimulator), were detected, together 
with CD54 [intercellular adhesion molecule (ICAM)-1] 
and CD50 (ICAM-3); ligands of lymphocyte function-
associated antigen 1 (LFA-1) required for NK cell and T 
cell-mediated cytotoxicity [30]. The GSC cell surface screen 
therefore revealed expression of a repertoire of targetable 
cell surface molecules with the potential to activate and 
inhibit NK cells, T cells and myeloid cells. This prompted 
us to explore the expression of immunosuppressive path-
ways in more detail, using a publicly available GBM single-
cell gene expression data set [18]. Among 3589 single 
cells, we identified 757 co-expressing SOX2 and EGFR 
(defined by Darmanis et al. [18] as tumour cells) and 
1527 cells expressing PTPRC (encoding CD45, a marker 
of cells of haematopoietic origin.) We next performed 
unsupervised hierarchial clustering using expression of 
lineage marker genes and genes encoding candidate immu-
nosuppressive functions, which identified two main groups: 
non-immune (comprising tumour and neuronal cells) and 
immune cells (PTPRC+) (Fig. 3b). The immune cell group 
was dominated by expression of numerous myeloid cell 
markers (Fig. 3b). Genes encoding immunosuppressive 
functions were expressed within both the immune and 
non-immune clusters (Fig. 3b) and, overall, individual 
immune cells expressed a greater number of immunosup-
pressive genes than tumour cells (Supporting information, 
Fig. S3A). Consistent with the altered cell surface phenotype 
of GBM-resident NK cells (Fig. 2a), we found widespread 
expression of TGFB family transcripts accounted for by 
TGFB1 expression in the myeloid cells and TGFB2 and 
TGFB3 expression in non-immune cells. Furthermore, 
human leucocyte antigen G (HLA-G) (which plays a key 
role in regulating NK cell activity in pregnancy and cancer 
[31,32]) was also widely expressed. The HLA-G protein 
inhibits myeloid cells via receptors leucocyte immuno-
globulin-like receptor subfamily B member 1 (LILRB)1 
and LILRB2 [31], both of which were expressed in the 
immune compartment at the mRNA level. We identified 
strong expression of the receptor-ligand pair hepatitis A 
virus cellular receptor 1 (HAVCR1) (TIM3) and lectin, 
galactose binding, soluble 9 (LGALS9) in the myeloid 
cluster (92% of immune cells expressed HAVCR2 or 
LGALS9 and 60% expressed both genes; Supporting infor-
mation, Fig. S3B). This scRNA-seq data along with the 
GSC surface antigen screen shows that both tumour and 
immune infiltrating cells express receptors and ligands 
that together constitute a complex network of immuno-
suppression. For example, the combined action of CD73 
and CD39 generate immunosuppressive adenosine [29]; 
our data show expression of CD73 by the tumour cells 
Fig. 3. The repertoire of immunosuppressive molecules expressed in glioblastoma (GBM). (a) Expression of selected cell surface antigens on GBM 
stem-like cell (GSC) lines; the data show expression by GBM20. A summary of expression across the four GSC lines is provided in Supporting 
information, Table S1. (b) Single-cell (sc) RNAseq data [18] were clustered, revealing immune and tumour groups marked by protein tyrosine 
phosphatase receptor type C (PTPRC) and SRY-box transcription factor 9 (SOX9/EGFR co-expression, respectively. Expression of marker genes for 
cell lineages and those encoding immunomodulatory molecules are indicated. Expression is scored according to the values and key shown.
(a) (b)
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(Fig. 3a) and 5’-nucleotidase ecto (NT5E) (encoding CD39) 
by the immune fraction (Fig. 3b), with Mohme et al. 
demonstrating CD39 expression by GBM-infiltrating 
T cells [13].
Furthermore, to assess whether this immunosuppressive 
network was induced in response to tumour, we analysed 
gene expression data derived from normal brain tissue [33] 
(Supporting information, Fig. S4). Microglia/macrophages 
(the only cell population in the normal brain expressing 
PTPRC/CD45) constitutively express several immunosup-
pressive genes, including immune checkpoints V-set immu-
noregulatory receptor (VSIR) and HAVCR2 and checkpoint 
ligands LGALS9, CD274 and PDCD1LG2. Some components 
of the immunosuppressive network found in brain tumours 
are therefore present in the healthy brain.
A spectrum of immune activity in GBM patients
We have previously used tumour transcriptome data to 
cluster melanoma patients according to their immune cell 
infiltrate [14]. This approach identified six CICs, with one 
cluster enriched in cytotoxic cells (CIC2) and another 
(CIC4) having low immune infiltrates and significantly 
worse survival [14]. We used this approach to classify 
GBM transcriptome data (from TCGA) and, like the situ-
ation in melanoma, the cohort of 154 patients clustered 
into the six CICs (Fig. 4a), with two main clusters CIC2 
(high immune infiltrate) and CIC4 (low immune infiltrate). 
We found that CIC2 was significantly enriched for tumours 
of the mesenchymal subtype [34] (Supporting information, 
Table S2) that has been previously shown to have pro-
longed survival [21]. However, unlike melanoma [14], 
immune infiltration (reflected in the CIC clusters) was 
not associated with significant differences in survival in 
GBM (Supporting information, Fig. S5). There was also 
no significant difference in mutation burden, a surrogate 
of neoantigen load reflecting immunogenicity [8,9], between 
CIC2 and CIC4 in GBM (Fig. 4b). These data demonstrate 
that patients can be stratified based on the immune infil-
trate but that, unlike melanoma, this stratification has no 
effect on patient outcomes under the conditions of treat-
ment currently employed.
Immune activation induces feedback inhibitory path-
ways, including the expression of immune checkpoint 
molecules, and we therefore attempted to use the expres-
sion of genes in these pathways to understand the immune 
environment within the GBM CIC clusters. To do this 
we compared expression of anti-tumour effector functions 
and immunomodulatory genes in CIC2 and CIC4. 
Expression of the granzyme B (GZMB) and interferon 
(IFN)-γ genes were significantly higher in CIC2 than 
CIC4, consistent with the increased infiltration of cytotoxic 
T cells and NK cells (Fig. 4c). Furthermore, genes encod-
ing immune checkpoint molecules (CTLA-4, PDCD1, 
HAVCR2, BTLA and VSIR), their ligands (PDCD1LG2, 
LGALS9) and forkhead box protein 3 (FoxP3) were a 
lso expressed at significantly higher levels in CIC2 than 
CIC4 (Fig. 4d), as were genes encoding soluble mediators 
of immunosuppression such IL-10, TGF-β1 and IDO1 
(Fig. 4e). To confirm this we used microarray data from 
the REMBRANDT study [17] and GZMA gene expression 
as a simple surrogate for immune infiltration [35]. This 
analysis confirmed the significantly higher expression of 
multiple immunosuppressive functions in patients with 
increased expression of anti-tumour effector functions 
(Supporting information, Fig. S6). Collectively, these data 
drive our understanding of the GBM immune microen-
vironment, demonstrating a spectrum of immune infiltration, 
functionally compromised by an active immune-inhibitory 
network.
Discussion
Our analysis demonstrates tumour and immune-mediated 
immunosuppression within the GBM tumour microenvi-
ronment, functionally inactivating GBM anti-tumour 
immunity. We demonstrate reduced expression of tumour-
sensing activating receptors on GBM-resident NK cells 
consistent with TGF-β activity [26]. The TGF-β family 
cytokines play a manifold role in glioma progression, 
including maintenance of the GSC pool, proliferation, 
invasion, angiogenesis and immunosuppression [36]. 
Multiple mechanisms of tumour-mediated down-regulation 
of NK cell activation receptors have been identified. 
However, we favour TGF-β as a modulator of the NK 
cell phenotype in GBM, as we show reduced expression 
of activation receptors coupled with increased expression 
of CD9, a tetraspanin induced by TGF-β in NK cells 
[28]. Mohme et al. showed that infiltrating T cells expressed 
PD-1, TIM-3 and CD39 [13], characteristic of T cell 
exhaustion [37]. Our analysis extended these findings by 
identifying CTLA-4 and LAG-3 on GBM-infiltrating T 
cells. Thus, GBM-infiltrating NK cells have reduced expres-
sion of activating receptors, whereas T cells have increased 
expression of immune checkpoint molecules, resulting in 
inhibition of both classes of cytotoxic lymphocytes. 
Furthermore, we identified CD73 on the GSC cell surface, 
and together with CD39 on infiltrating T cells these ecto-
nucleosidases may act together to generate immunosup-
pressive adenosine which inhibits both NK cells and T 
cells [29]. Similar to Castriconi et al. [38], we demonstrate 
that activated NK cells are capable of recognizing and 
killing GSC cell lines in vitro, and we further show that 
NK cells discriminate between the GSC and a normal 
neural progenitor cell line.
The analysis of NK cells in GBM and their interaction 
with GSCs led to a more extensive analysis of the 
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immunosuppressive network. Our data highlight the abun-
dance of immunosuppressive pathways operating in GBM. 
The most abundant immune cells in GBM belong to the 
myeloid lineage [12], and we show that GSCs express cell 
surface molecules such as PD-L1 and CD47, which inhibit 
phagocytosis by macrophage [18,39,40]. These data dem-
onstrate that immune inhibition within GBM is mediated 
by both immune and non-immune lineages co-operating 
to provide a pro-tumour environment. Interestingly, CD47 
and CD200 are important regulators of microglial activity 
and brain inflammation in non-malignant disease [41]. 
The single-cell transcriptome data reveal the extent of 
candidate pathways operating in GBM. Many of these 
molecules have been detected at the protein level on GBM 
tumour cells and immune infiltrates, both in this study 
using flow cytometry of GSCs and infiltrating lymphocytes 
(e.g. immune checkpoints, checkpoint ligands and ecto-
nucleosidases), as well as in previous studies, using immu-
nohistochemistry and flow cytometry [42–46].
Several of the immunosuppressive pathways evident in 
GBM are in place in the normal brain. In response to 
TGF-β, microglia suppress immunological activity and 
promote normal microglial functions such as synaptic 
pruning and neuronal growth support [47]. The expression 
of genes such as HAVCR2 and its ligand LGALS9 and 
CD274, together with TGFB2 and IL-10, safeguard the 
normal brain against excessive inflammation [48]. Muller 
et al. demonstrate that infiltrating macrophages rather than 
resident microglia encode immunosuppressive cytokines 
within the GBM microenvironment [49]. Thus, immuno-
suppressive pathways operating in the GBM-free brain 
are utilized and extended upon by infiltrating myeloid 
cells, contributing to the extensive immunosuppressive 
network.
The identification of a spectrum of immune infiltration 
across the GBM cohort, accompanied by evidence of anti-
tumour effector function and feedback inhibitory pathways, 
suggests that GBM should not simply be regarded as an 
immunogenically ‘cold’ tumour. The high expression of 
mutiple feedback inhibitors, together with high expression 
of GZMB and IFN-γ in CIC2, identifies ongoing, or at 
least prior, immune activation in a subset of GBM patients, 
restrained by the action of these inhibitory pathways.
Indeed, melanoma shows interpatient heterogeneity of 
immune responses, and regarding melanoma as ‘hot’ fails 
to account for this variability. In melanoma, immune 
heterogeneity impacts upon survival [14] and the success 
of immunotherapy, with high expression of PD-1, CD8+ 
T cell infiltration and higher mutational burden associat-
ing with response to therapy [9]. We found no evidence 
for differential survival in GBM according to our CIC 
classifications, suggesting that the extensive immunosup-
pressive network removes any impact of immune control 
on  GBM progression. However, these survival data are 
based on standard therapy and, by analogy with melanoma, 
we suggest that GBM CIC2 patients are more likely to 
respond to immunotherapy. Moreover, the extensive immu-
nosuppressive network suggests that targeting multiple 
inhibitory pathways will be a probable requirement of 
GBM immunotherapy.
The mechanisms underlying interpatient heterogeneity 
of immune response in GBM are unclear [50]. β-catenin-
mediated immune evasion pathways operate in CIC4, the 
group with the poorest prognosis in melanoma [14], 
whereas in this study we found no evidence of CTNNB1 
differential expression between CIC2 and CIC4, nor was 
their mutational burden significantly different. However, 
GBM arises through various combinations of oncogene 
and tumour suppressor mutations, and several of these 
genes regulate tumour immune responses [51,52]. Thus, 
differences in oncogene and/or tumour suppressor gene 
mutations between patients is one potential factor under-
lying the spectrum of immune activity seen across the 
GBM cohort.
GSCs are effective targets of NK cells ex vivo, but GBM-
infiltrating NK cells have a surface phenotype bearing the 
hallmarks of TGF-β-mediated immunosuppression. Further 
exploration of immunosuppressive pathways using gene 
and protein profiling indicated that both tumour and 
immune cell components contribute inhibitory factors. 
These pathways are a barrier to effective immunotherapy, 
but also represent candidate therapeutic targets. Combined 
checkpoint blockade is already outperforming monotherapy 
in melanoma  [46]. Targeting combinations of the multiple 
immune checkpoints (PD-1, LAG-3, CTLA-4, TIM-3, VSIR/
VISTA) or other immunosuppressive molecules (e.g. ecto-
nucleosidases, TGF-B, IL-10) may prove beneficial in GBM. 
Strategies to activate NK cells in situ, e.g. via the use of 
oncolytic viruses [53–55] and methods to alter the immune 
composition of GBM, will also benefit from alleviating 
key immunosuppressive pathways. Importantly, GBM is 
not universally devoid of immune activity, and a subset 
Fig. 4. A spectrum of immune activity in glioblastoma (GBM). (a) Classification of GBM tumours [from 154 patients in the The Cancer Genome Atlas 
(TCGA) data set] into consensus immunome clusters (CIC) using the nearest centroid classification. The number of patients in each CIC is indicated 
in brackets. The cell signatures used to derive the CIC [14] are shown. (b) Mutational load in GBM CIC2 (red) and CIC4 (green) expressed as 
mutations per megabase. (c) Expression of granzyme B (GZMB) and interferon gamma (IFN-γ) in CIC2 (red) and CIC4 (green). (d) Expression of 
negative regulators of immunity in CIC2 (red) and CIC4 (green). (e) Expression of cytokines and enzymes associated with immunosuppressive 
activity. (b–e) Data from CIC2 and CIC4 were compared using the Mann–Whitney test; n.s. = not significant, *P < 0·05, **P < 0·01, ***P < 0·001, 
****P < 0·0001.
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of patients with evidence of immune activity suggests that 
combinatorial immunotherapy would be most effective 
when patients are stratified according to immune 
infiltrates.
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